EMB-09 / EpimAb Biotherap - LARVOL DELTA

A novel designed anti-PD-L1/OX40 bispecific antibody augments both peripheral and tumor-associated immune responses for boosting anti-tumor immunity. (PubMed, Mol Cancer Ther) - P1 | "Significantly, EMB-09 activated effector memory T cells in peripheral immune system, promoted the influx of stem-like CD8+ T cells into the tumor site, resulting in a more active phenotype of CD8+ tumor-infiltrating lymphocytes. In an ongoing first-in-human study in patients with advanced refractory solid tumors (NCT05263180), EMB-09 demonstrated a consistent pharmacodynamic response and early efficacy signals."

Journal • Oncology • Solid Tumor • CD27 • CD8

A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Shanghai EpimAb Biotherapeutics Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Breast Cancer • Colorectal Cancer • Endometrial Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hepatocellular Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer

A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Shanghai EpimAb Biotherapeutics Co., Ltd.

New P1 trial • Breast Cancer • Colorectal Cancer • Endometrial Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hepatocellular Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer